Prostate Cancer Awareness and Initiative for Screening in the European Union
Launched by EUROPEAN ASSOCIATION OF UROLOGY RESEARCH FOUNDATION · May 16, 2024
Trial Information
Current as of August 19, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The PRAISE-U trial is a new study aimed at improving prostate cancer screening in Europe. Starting in April 2023 and running for three years, this project involves 25 institutions across 12 countries. The goal is to develop better methods for detecting prostate cancer early, so men who need treatment can get it as soon as possible. The trial will test a risk-based approach, which means they will identify individuals who might be at higher risk for prostate cancer and focus on screening them. The study will take place at pilot sites in Spain, Poland, Ireland, and Lithuania.
To participate in this trial, men aged 50 to 69 years old may be eligible, as long as they haven't been diagnosed with prostate cancer before and haven't had a prostate biopsy or MRI in the last six months. Participants can expect to be part of a program that aims to create better screening standards and improve health outcomes for men at risk of prostate cancer. This study is not yet recruiting participants, but it represents an important step toward personalized care for prostate cancer in Europe.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Age 50-69 years old.
- Exclusion Criteria:
- • Previous diagnosis of prostate cancer.
- • Unable to provide written informed consent.
- • Had prostate biopsy or MRI within the past six months.
About European Association Of Urology Research Foundation
The European Association of Urology Research Foundation (EAU-RF) is a prominent organization dedicated to advancing scientific research and innovation in the field of urology. As a sponsor of clinical trials, EAU-RF aims to enhance the understanding of urological conditions and improve patient outcomes through rigorous research initiatives. The foundation fosters collaboration among researchers, healthcare professionals, and industry stakeholders, promoting the dissemination of knowledge and best practices in urological care. By supporting high-quality studies, EAU-RF plays a pivotal role in driving evidence-based advancements and shaping the future of urological health across Europe and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dublin, , Ireland
Vilnius, , Lithuania
Wrocław, Lower Silesia, Poland
Santiago De Compostela, Galicia, Spain
Manresa, , Spain
Patients applied
Trial Officials
Hendrik Van Poppel, Prof
Study Director
European Association of Urology and KULeuven
Monique J Roobol, Prof
Principal Investigator
Erasmus MC Cancer Institute Dep of Urology and European Association of Urology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported